Before a medicine reaches patients, it must be proven safe and effective through years of scientific research. LuciNfig (infigratinib) is supported by strong clinical and preclinical studies that show its benefits in both pediatric growth disorders and rare FGFR-driven cancers.
Here’s what the data tells us:
1. PROPEL2 Phase 2 trial – Achondroplasia in Children
One of the most promising studies is the PROPEL2 Phase 2 trial (Cohort 5), which focused on children with achondroplasia.
- Participants: 72 children (mostly under 12 years old)
- Treatment: Low‑dose LuciNfig (~0.25 mg/kg daily)
- Duration: 18 months
- Results:
- Average growth rate improved by +2.5 cm per year
- Steady and continuous growth observed
- No children stopped treatment due to side effects
Why it matters:
This study shows that LuciNfig can help children grow taller in a more balanced way—without the need for painful surgeries or injections. It also improved body proportions, which helped many children move more freely and comfortably.
2. Preclinical Animal Studies – Understanding Bone Growth at the Cellular Level
Before human trials, LuciNfig was tested in animal models that mimic achondroplasia.
- Key findings:
- Restored normal growth plate structure (essential for bone elongation)
- Corrected skull base abnormalities
- No signs of phosphate imbalance (a common side effect of some FGFR treatments)
Why it matters:
These studies confirmed that LuciNfig could safely target the biological cause of achondroplasia, paving the way for safe use in children.
3. Cancer Trials – LuciNfig for FGFR-Related Cancers
LuciNfig is also being explored as a targeted cancer therapy for conditions linked to FGFR mutations.
a. Cholangiocarcinoma (Bile Duct Cancer)
- Received FDA accelerated approval on May 28, 2021 under the brand name Truseltiq
- Used in adults with FGFR2 gene fusions
- Showed significant [tumor shrinkage] and disease control
- Withdrawn in May 2024 for business reasons—not due to safety or effectiveness (fda.gov, pubmed.ncbi.nlm.nih.gov, bridgebio.com)
b. Gastric Cancer (China – Breakthrough Therapy Designation)
- In early trials, LuciNfig showed promise in advanced stomach cancers with FGFR2 changes
- Received Breakthrough Therapy status in China in 2023
c. Gliomas and Solid Tumors
- Currently being studied in recurrent brain tumors and a variety of solid tumors
- Part of “pan-cancer” studies that focus on gene mutations regardless of tumor location
Why it matters:
These trials demonstrate LuciNfig’s potential in precision oncology, offering new options for patients with hard-to-treat cancers.
Summary of LuciNfig Research
| Trial / Study | Condition | Key Outcome |
|---|---|---|
| PROPEL2 (Phase 2, Cohort 5) | Achondroplasia in children | +2.5 cm/year growth, better body proportions |
| Preclinical (Animal Models) | Achondroplasia model | Normalized bone structure, no phosphate imbalance |
| Cholangiocarcinoma Trials | FGFR2-positive cancer | Tumor control; FDA approval in 2021, withdrawn 2024 |
| Gastric Cancer (China) | FGFR2-amplified stomach tumors | Breakthrough designation for further development |
| Glioma / Pan-Tumor Trials | Various FGFR-related cancers | Ongoing, early signs of targeted treatment potential |
LuciNfig continues to show promise as both a growth therapy and a precision cancer treatment. With each trial, more families and patients may soon have access to this science-backed solution.
